Choose Your Cannabis Method
Tirzepatide (Mounjaro, Zepbound) — All Methods🍬 Edibles — 2–4+ hours
Tirzepatide + Edibles
Gummies, Chocolates, Capsules, Baked Goods
⚠️ Caution
⚠️ Caution
🌿 Smoking — 1–10 minutes
Tirzepatide + Smoking
Flower, Pre-Rolls, Joints, Pipes
🔵 Moderate
🔵 Moderate
💨 Vaping — 1–10 minutes
Tirzepatide + Vaping
Cartridges, Disposable Vapes, Dry Herb Vaporizers
🔵 Moderate
🔵 Moderate
💧 Tinctures — Sublingual component unchanged; swallowed portion delayed 2–4+ hours
Tirzepatide + Tinctures
Sublingual Drops Held Under the Tongue
🔵 Moderate
🔵 Moderate
🫙 CBD Oil — Oral: delayed 2–4+ hours on GLP-1; sublingual component less affected
Tirzepatide + CBD Oil
Oral CBD Drops, Softgels, High-CBD Tinctures
🔵 Moderate
🔵 Moderate
About Tirzepatide: The GLP-1 Gastric Slowing Effect
Why Method MattersAs a dual GIP/GLP-1 receptor agonist, tirzepatide produces gastric emptying delay consistent with or exceeding single-agonist GLP-1 medications. Oral cannabis products are subject to the same unpredictable absorption delay that applies across the GLP-1 class, and possibly more pronounced given the dual agonist mechanism.
| Method | Affected by GLP-1? | Onset on Tirzepatide | Primary Risk |
|---|---|---|---|
| Edibles | Yes — significantly delayed | 2–4+ hours | ⚠️ Caution |
| Smoking | No — lung absorption | 1–10 min (unchanged) | 🔵 Moderate |
| Vaping | No — lung absorption | 1–10 min (unchanged) | 🔵 Moderate |
| Tinctures | Partial — depends on technique | Mixed (15 min–4+ hours) | 🔵 Moderate |
| CBD Oil | Yes — oral absorption delayed | 2–4+ hours | 🔵 Moderate |
Check Your Full Medication List
Taking Tirzepatide plus other medications? Use InteractSafe to review your complete combination.
Tirzepatide + Cannabis Full Profile →Or open the full interaction checker · Free · No account required
Other GLP-1 Medications
Compare by DrugGLP-1 Guide
Semaglutide (Ozempic)
GLP-1 receptor agonist
GLP-1 Guide
Orforglipron (Foundayo)
Oral GLP-1 receptor agonist (small molecule)
GLP-1 Guide
Dulaglutide (Trulicity)
GLP-1 receptor agonist
GLP-1 Guide
Liraglutide (Victoza)
GLP-1 receptor agonist
GLP-1 Guide
Exenatide (Byetta)
GLP-1 receptor agonist
GLP-1 Guide
Retatrutide (No brand name assigned (Phase 3 clinical trials as of June 2026))
GLP-1/GIP/Glucagon triple receptor agonist (investigational)